CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Activities
Net (loss) income	$ (331,942)	$ 109,625
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	28,229	33,396
Amortization of debt issuance costs and Royalty Rights	455	304
Loss on impairment of intangible assets	279,639	0
Gain on extinguishment of debt	0	(1,046)
Recurring fair value measurements of assets and liabilities	(25,482)	18,939
Debt-related expenses	9,918	0
Stock-based compensation	9,158	7,504
Provisions for inventory and other assets	3,288	3,265
Deferred income taxes	76,201	(80,375)
Changes in assets and liabilities, net of acquisition:
Accounts receivable	48,669	(996)
Inventories	(4,973)	(6,593)
Prepaid and other assets	(1,169)	8,019
Accounts payable and other accrued liabilities	(29,348)	(10,113)
Accrued rebates, returns and discounts	(12,313)	(3,236)
Interest payable	(726)	(95)
Net cash provided by operating activities	49,604	78,598
Investing Activities
Purchases of property and equipment	(628)	(274)
Net cash acquired in Spectrum Merger	1,950	0
Proceeds from the sale of investments	2,194	0
Net cash provided by (used in) investing activities	3,097	(42,673)
Financing Activities
Proceeds from issuance of 2027 Convertible Notes	0	70,000
Payments in connection with 2027 Convertible Notes	(10,500)	0
Payment of direct transaction costs related to convertible debt inducement	(1,119)	0
Payment in connection with 2024 Senior Notes	0	(70,750)
Payment of debt issuance costs	0	(4,084)
Payment of contingent consideration	(24,194)	(7,845)
Payment of Royalty Rights	(459)	(1,297)
Proceeds from issuance of common stock	0	7,020
Payments related to the vesting and settlement of equity awards, net	(7,898)	(838)
Other financing activities	(31)	0
Net cash used in financing activities	(44,201)	(7,794)
Net increase in cash and cash equivalents	8,500	28,131
Cash and cash equivalents at beginning of year	64,941	36,810
Cash and cash equivalents at end of year	73,441	64,941
Supplemental Disclosure of Cash Flow Information
Net cash paid (refunded) for income taxes	4,031	(6,913)
Cash paid for interest	3,651	7,752
Otrexup
Investing Activities
Purchase of Otrexup and Sympazan	0	(27,027)
Sympazan
Investing Activities
Purchase of Otrexup and Sympazan	$ (419)	$ (15,372)